Latuda
Generic Name
Lurasidone
Manufacturer
Sunovion Pharmaceuticals Inc. (original developer)
Country
USA
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| latuda 20 mg tablet | ৳ 20.00 | ৳ 200.00 |
Description
Overview of the medicine
Lurasidone (Latuda) is an atypical antipsychotic medication used to treat schizophrenia in adults and adolescents, and depressive episodes associated with bipolar I disorder in adults and pediatric patients.
Uses & Indications
Dosage
Adults
Schizophrenia: Initial dose is 40 mg/day, target dose 40-160 mg/day. Bipolar Depression: Initial dose is 20 mg/day, target dose 20-120 mg/day. Administer once daily with food.
Elderly
No specific dose adjustment based on age, but consider lower starting doses and slower titration due to potential for greater sensitivity to adverse effects.
Renal_impairment
For moderate to severe renal impairment (creatinine clearance < 50 mL/min), the maximum recommended dose is 80 mg/day. For end-stage renal disease, max dose 40 mg/day.
How to Take
Take Latuda orally once daily with food (at least 350 calories). Taking it without food significantly reduces its absorption and effectiveness.
Mechanism of Action
Lurasidone primarily acts as an antagonist at dopamine D2 and serotonin 5-HT2A receptors, and a partial agonist at serotonin 5-HT1A receptors. It also antagonizes alpha2C adrenergic receptors. This modulation of neurotransmitter activity contributes to its antipsychotic and mood-stabilizing effects.
Pharmacokinetics
Onset
Clinical effects may be observed within a few weeks of consistent use, with full therapeutic benefits taking longer.
Excretion
Mainly excreted via feces (approximately 80%) and urine (approximately 9%).
Half life
Approximately 18 hours.
Absorption
Well absorbed after oral administration, with peak plasma concentrations occurring within 1-3 hours. Bioavailability is approximately 9-19% and is significantly increased when taken with food.
Metabolism
Extensively metabolized in the liver, primarily by the cytochrome P450 enzyme CYP3A4. Its major active metabolites have similar receptor binding profiles to the parent drug.
Side Effects
Contraindications
- •Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) due to significant increase in lurasidone exposure.
- •Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) due to significant decrease in lurasidone exposure.
- •Hypersensitivity to lurasidone or any component of the formulation.
Drug Interactions
Antihypertensives
May enhance orthostatic hypotensive effects.
Strong CYP3A4 Inducers (e.g., rifampin)
Concomitant use is contraindicated; significantly decreases lurasidone plasma concentrations.
Strong CYP3A4 Inhibitors (e.g., ketoconazole)
Concomitant use is contraindicated; significantly increases lurasidone plasma concentrations.
CNS Depressants (e.g., alcohol, benzodiazepines)
May potentiate the sedative effects of lurasidone.
Moderate CYP3A4 Inducers (e.g., bosentan, efavirenz)
Increase lurasidone dose if needed. Monitor for reduced efficacy.
Moderate CYP3A4 Inhibitors (e.g., diltiazem, erythromycin)
Reduce lurasidone dose to half of the original dose. Monitor for adverse effects.
Storage
Store at controlled room temperature (20-25°C or 68-77°F); excursions permitted to 15-30°C (59-86°F). Protect from moisture and light. Keep out of reach of children.
Overdose
Management of overdose is primarily supportive, including maintaining an adequate airway, oxygenation, and ventilation. Gastric lavage and administration of activated charcoal may be considered shortly after ingestion. Monitor cardiovascular status, including continuous ECG monitoring for possible arrhythmias. No specific antidote exists.
Pregnancy & Lactation
Pregnancy Category C. May cause extrapyramidal and/or withdrawal symptoms in neonates upon exposure during the third trimester. Use only if the potential benefit justifies the potential risk to the fetus. Lurasidone is excreted in animal milk; it is not known whether it is excreted in human milk. Advise mothers not to breastfeed during treatment.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 to 36 months from the date of manufacture, depending on storage conditions.
Availability
Available in pharmacies worldwide
Approval Status
FDA Approved
Patent Status
Generic versions available in some regions since 2023.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
